Hospira Recalls Ketorolac Tromethamine Injections Due to Sterility Concerns
Hospira, Inc. is recalling 345,800 vials of Ketorolac Tromethamine Injection due to a lack of assurance of sterility caused by loose or missing crimps on fliptop vials.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves a risk of harm (infection) from a sterile product where injury has not yet been reported, fitting the 'High' severity criteria for risk-of-harm products.
Plain-English summary
Hospira, Inc. is recalling 345,800 vials of Ketorolac Tromethamine Injection, USP, 30 mg. The recall involves Lot 25048DK with an expiration date of 01/15. The product is distributed nationwide.
The recall was initiated because there is a lack of assurance of sterility. Specifically, either a loose crimp or no crimp was applied to the fliptop vials, which compromises the integrity of the packaging.
Healthcare providers and patients should discontinue use of the affected vials. Consumers should check their medication for the specific lot number and expiration date listed above and contact their pharmacist or healthcare provider for guidance on replacement or disposal.
The recalled product
- Product
- KETOROLAC TROMETHAMINE (KETOROLAC TROMETHAMINE)
- Brand
- KETOROLAC TROMETHAMINE
- Manufacturer
- Hospira, Inc.
- Category
- Drug — Injection
- Affected units
- 345,800
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot 25048DK Exp. 01/15
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · KETOROLAC TROMETHAMINE
- HighKetorolac injection vials recalled after glass particulate found in product
FDA (Drugs) · 2025-10-29
- HighKetorolac ophthalmic solution recalled over sterility assurance and bottle sealing concerns
FDA (Drugs) · 2025-10-08
- SevereKetorolac Tromethamine Ophthalmic Solution Recalled for Sterility Risk
FDA (Drugs) · 2025-07-02
- HighInjectable ketorolac tromethamine recalled nationwide for potential cross-contamination
FDA (Drugs) · 2022-08-24
- SevereFresenius Kabi Recalls Ketorolac Tromethamine Injection Due to Particulate Matter
FDA (Drugs) · 2021-02-03
Same manufacturer · Hospira, Inc.
See all →- CriticalHospira Recalls Dextrose Injection Syringes Due to Human Hair Particulate
FDA (Drugs) · 2017-05-31
- ModerateHospira Recalls Minibore Extension Sets Due to Solvent Occlusion
FDA (Devices) · 2017-01-18
- LowHospira Recalls Lidocaine and Dextrose Injection for Stability Failures
FDA (Drugs) · 2016-12-14
- SevereHospira Recalls Fentanyl Citrate Injection Ampules Due to Broken Tips
FDA (Drugs) · 2016-11-30
- HighHospira Symbiq Infusion Pump Recall for White Screen Safety Shutdown
FDA (Devices) · 2016-11-16
Same hazard · sterility
See all →- SevereRegeneron Recalls Libtayo Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-08-26
- SeverePrestige Recalls Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns
FDA (Drugs) · 2026-08-19
- SevereROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SevereFDA Recalls ROHTO OPTIC GLOW Eye Drops Over Sterility Concerns
FDA (Drugs) · 2026-07-29